NASDAQ: MGRMMonogram Orthopaedics Inc Stock
$2.33+0.06 (+2.64%)
Updated Apr 24, 2024
MGRM Price
$2.33
Fair Value Price
$0.58
Market Cap
$73.71M
52 Week Low
$1.53
52 Week High
$48.99
P/E
-3.82x
P/B
5.5x
P/S
211.2x
PEG
N/A
Dividend Yield
N/A
Revenue
$365.00k
Earnings
-$13.75M
Gross Margin
100%
Operating Margin
-3,765.82%
Profit Margin
-3,765.8%
Debt to Equity
0.24
Operating Cash Flow
-$14M
Beta
1.31
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MGRM Overview
Monogram Orthopaedics, Inc. focuses on developing a product solution architecture to enable mass personalized optimization of orthopedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures. Its robot prototype executes optimized paths for high-precision insertion of optimized implants in synthetic bone specimens. The company was formerly known as Monogram Arthroplasty Inc. and changed its name to Monogram Orthopaedics, Inc. in March 2017. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how MGRM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MGRM ($2.33) is overvalued by 299.63% relative to our estimate of its Fair Value price of $0.58 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
MGRM ($2.33) is not significantly undervalued (299.63%) relative to our estimate of its Fair Value price of $0.58 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
MGRM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more MGRM due diligence checks available for Premium users.
Be the first to know about important MGRM news, forecast changes, insider trades & much more!
MGRM News
Valuation
MGRM fair value
Fair Value of MGRM stock based on Discounted Cash Flow (DCF)
Price
$2.33
Fair Value
$0.58
Overvalued by
299.63%
MGRM ($2.33) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
MGRM ($2.33) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
MGRM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
MGRM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.82x
Industry
30.46x
Market
41.27x
MGRM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.5x
Industry
3.73x
MGRM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MGRM's financial health
Profit margin
Revenue
$365.0k
Net Income
-$3.7M
Profit Margin
-1,001.2%
MGRM's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
MGRM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$16.6M
Liabilities
$3.2M
Debt to equity
0.24
MGRM's short-term assets ($14.62M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MGRM's short-term assets ($14.62M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MGRM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MGRM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.1M
Investing
-$24.1k
Financing
$1.8M
MGRM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MGRM vs Medical Device Stocks
Monogram Orthopaedics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.